Lilly has commenced a new feasibility study assessing the functionality and safety of a new automated insulin delivery system.
The new system is a hybrid closed-loop platform that uses connected devices - including an insulin pump with a dedicated controller, dosing algorithm and continuous glucose monitor - to automate insulin dosing.
“Lilly has commenced a clinical trial to evaluate the functionality and safety of its new automated insulin delivery system.“
These components are designed to work together to automatically adjust infusion rates to maintain blood sugar levels within a specified range, and is part of Lilly's Connected Diabetes Ecosystem, which is designed to make diabetes management easier.
The first patient with type 1 diabetes has already been enrolled for the study, which will help to support future regulatory approvals and aid the company's goal of commercialising the platform within the next two or three years.
Marie Schiller, Lilly's vice-president of connected care and site head of the Cambridge Innovation Center, said: "This trial is a significant step forward for Lilly's Connected Care programme, moving the Connected Diabetes Ecosystem closer to hopefully becoming available to the millions of people with diabetes who need a simpler, more effective way to use insulin."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical